Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Pharma Industry Analysis

UpdatedOct 04, 2025
DataAggregated Company Financials
Companies22
  • 7D2.2%
  • 3M2.2%
  • 1Y1.6%
  • YTD8.7%

The Pharma industry is up 1.5% in the last week, with Camurus up 2.5%. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 42% annually.

Industry Valuation and Performance

Has the Swedish Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 04 Oct 2025SEK 55.1bSEK 5.1b-SEK 405,183,865.0070.9x-136.1x10.9x
Mon, 01 Sep 2025SEK 57.9bSEK 5.1b-SEK 405,183,865.0079.1x-142.9x11.4x
Wed, 30 Jul 2025SEK 57.5bSEK 5.0b-SEK 375,088,364.0078.6x-153.2x11.4x
Fri, 27 Jun 2025SEK 50.3bSEK 4.8b-SEK 574,661,033.9266.7x-87.5x10.4x
Sun, 25 May 2025SEK 44.2bSEK 4.8b-SEK 596,640,173.5959.8x-74x9.1x
Tue, 22 Apr 2025SEK 47.4bSEK 4.7b-SEK 911,478,077.3967.5x-52.1x10.1x
Thu, 20 Mar 2025SEK 50.9bSEK 4.7b-SEK 809,586,885.6472.8x-62.9x10.8x
Sat, 15 Feb 2025SEK 51.3bSEK 4.7b-SEK 840,238,890.83120x-61.1x11x
Mon, 13 Jan 2025SEK 51.5bSEK 4.4b-SEK 615,786,090.60132.8x-83.7x11.6x
Wed, 11 Dec 2024SEK 51.2bSEK 4.4b-SEK 615,962,301.13137.5x-83.1x11.5x
Fri, 08 Nov 2024SEK 53.6bSEK 4.3b-SEK 681,805,266.36132.5x-78.7x12.3x
Sun, 06 Oct 2024SEK 65.7bSEK 5.9b-SEK 1,157,224,367.43166.7x-56.8x11.2x
Tue, 03 Sep 2024SEK 69.7bSEK 5.9b-SEK 1,166,314,317.08186.2x-59.7x11.8x
Thu, 01 Aug 2024SEK 68.8bSEK 5.6b-SEK 992,833,131.5296.4x-69.3x12.3x
Sat, 29 Jun 2024SEK 66.8bSEK 6.4b-SEK 862,448,918.9878.1x-77.5x10.5x
Mon, 27 May 2024SEK 53.3bSEK 6.4b-SEK 766,510,517.9371.7x-69.5x8.4x
Wed, 24 Apr 2024SEK 48.5bSEK 6.2b-SEK 1,026,433,957.4676.7x-47.2x7.8x
Fri, 22 Mar 2024SEK 51.8bSEK 6.2b-SEK 1,038,087,086.8175.2x-49.9x8.3x
Sun, 18 Feb 2024SEK 47.2bSEK 6.1b-SEK 936,407,075.2980.6x-50.4x7.7x
Tue, 16 Jan 2024SEK 72.2bSEK 9.5b-SEK 1,182,137,361.0070.2x-61.1x7.6x
Thu, 14 Dec 2023SEK 65.5bSEK 9.4b-SEK 1,184,546,389.0060.4x-55.3x6.9x
Sat, 11 Nov 2023SEK 57.6bSEK 9.5b-SEK 1,228,334,855.0089.7x-46.9x6.1x
Mon, 09 Oct 2023SEK 51.2bSEK 9.2b-SEK 1,180,572,714.00116.3x-43.4x5.6x
Wed, 06 Sep 2023SEK 50.9bSEK 9.2b-SEK 1,177,925,495.00140.2x-43.2x5.5x
Fri, 04 Aug 2023SEK 51.0bSEK 8.9b-SEK 1,411,162,001.0091.1x-36.1x5.7x
Sun, 02 Jul 2023SEK 47.4bSEK 8.4b-SEK 1,692,681,920.0072.9x-28x5.7x
Tue, 30 May 2023SEK 49.1bSEK 8.4b-SEK 1,591,432,149.0078.8x-30.8x5.9x
Thu, 27 Apr 2023SEK 45.8bSEK 8.0b-SEK 1,791,818,812.00103.8x-25.5x5.7x
Sat, 25 Mar 2023SEK 44.6bSEK 8.0b-SEK 1,793,577,866.0083.8x-24.8x5.6x
Mon, 20 Feb 2023SEK 44.2bSEK 7.3b-SEK 1,980,325,844.00286.1x-22.3x6x
Wed, 18 Jan 2023SEK 50.0bSEK 7.3b-SEK 1,938,509,992.00283.1x-25.8x6.8x
Fri, 16 Dec 2022SEK 49.8bSEK 7.3b-SEK 1,876,028,486.00289.2x-26.5x6.8x
Sun, 13 Nov 2022SEK 49.2bSEK 6.8b-SEK 1,880,550,291.0057x-26.1x7.2x
Tue, 11 Oct 2022SEK 48.7bSEK 7.0b-SEK 1,739,929,483.0047.2x-28x7x
Price to Earnings Ratio

-28x


Total Market Cap: SEK 48.7bTotal Earnings: -SEK 1,739,929,483.00Total Revenue: SEK 7.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Pharma Industry Price to Earnings3Y Average -64.6x202320242025
Current Industry PE
  • Investors are optimistic on the Swedish Pharmaceuticals industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 8.6x is lower than the industry's current PS ratio of 10.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 10% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare industry?

SE Market2.72%
Healthcare3.45%
Pharma2.16%
Pharma2.16%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CAMX CamurusSEK 686.002.5%
+SEK 983.5m		4.0%PE56.9x
ORX OrexoSEK 38.7036.0%
+SEK 351.9m		168.8%PS2.4x
CLBIO Corline BiomedicalSEK 19.8536.4%
+SEK 129.8m		119.1%PS48.5x
SECARE SwedencareSEK 34.401.9%
+SEK 103.9m		-19.4%PE84.9x
CINPHA Cinclus Pharma HoldingSEK 17.348.1%
+SEK 60.5m		-40.6%PS20.9x

Latest News

ENZY
SEK 2.23
Enzymatica
7D
-5.5%
1Y
17.4%
ANNX
SEK 27.80
Annexin Pharmaceuticals
7D
-2.8%
1Y
-50.9%
ORX
SEK 38.70
Orexo
7D
36.0%
1Y
168.8%
MOB
SEK 8.41
Moberg Pharma
7D
-1.2%
1Y
-17.1%
SECARE
SEK 34.40
Swedencare
7D
1.9%
1Y
-19.4%
ERMA
SEK 2.38
Enorama Pharma
7D
-8.5%
1Y
-45.2%
CAMX
SEK 686.00
Camurus
7D
2.5%
1Y
4.0%

Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery

With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.
PILA
SEK 2.34
Pila Pharma
7D
9.3%
1Y
-56.7%
CLBIO
SEK 19.85
Corline Biomedical
7D
36.4%
1Y
119.1%
IBT B
SEK 66.70
Infant Bacterial Therapeutics
7D
-5.3%
1Y
101.5%
IRLAB A
SEK 2.85
IRLAB Therapeutics
7D
-4.4%
1Y
-77.7%
KLAR
SEK 0.50
Klaria Pharma Holding AB (publ.)
7D
-4.1%
1Y
-15.5%
ALZCUR
SEK 2.77
AlzeCure Pharma
7D
8.6%
1Y
45.8%
CINPHA
SEK 17.34
Cinclus Pharma Holding
7D
8.1%
1Y
-40.6%

PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally

Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.
FLERIE
SEK 42.50
Flerie
7D
1.7%
1Y
1.9%
DICOT
SEK 0.82
Dicot Pharma
7D
-3.5%
1Y
358.8%